Clinical use of immunoglobulins:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Bremen [u.a.]
UNI-MED-Verl.
2008
|
| Ausgabe: | 1. Aufl. |
| Schriftenreihe: | UNI-MED science
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | Literaturangaben |
| Beschreibung: | 207 S. Ill., graph. Darst. 25 cm |
| ISBN: | 9783837410112 9781848151284 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV035317097 | ||
| 003 | DE-604 | ||
| 005 | 20090218 | ||
| 007 | t | ||
| 008 | 090217s2008 ad|| |||| 00||| eng d | ||
| 015 | |a 09,A08,0987 |2 dnb | ||
| 016 | 7 | |a 992051355 |2 DE-101 | |
| 020 | |a 9783837410112 |c (Bremen ...) Pp. : EUR 44.80 |9 978-3-8374-1011-2 | ||
| 020 | |a 9781848151284 |c (London ...) Pp. |9 978-1-84815-128-4 | ||
| 035 | |a (OCoLC)461253218 | ||
| 035 | |a (DE-599)DNB992051355 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-19 |a DE-20 | ||
| 082 | 0 | |a 615.37 |2 22/ger | |
| 082 | 0 | |a 615.37 |2 22//ger | |
| 084 | |a 610 |2 sdnb | ||
| 245 | 1 | 0 | |a Clinical use of immunoglobulins |c [Volker Wahn ; Jordan Orange. In collab. with Ama Alexis ...] |
| 250 | |a 1. Aufl. | ||
| 264 | 1 | |a Bremen [u.a.] |b UNI-MED-Verl. |c 2008 | |
| 300 | |a 207 S. |b Ill., graph. Darst. |c 25 cm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 0 | |a UNI-MED science | |
| 500 | |a Literaturangaben | ||
| 650 | 4 | |a Immunglobulintherapie | |
| 650 | 4 | |a Immunization, Passive |x methods | |
| 650 | 4 | |a Immunoglobulins |x therapeutic use | |
| 650 | 0 | 7 | |a Immunglobulintherapie |0 (DE-588)4161377-6 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Immunglobulintherapie |0 (DE-588)4161377-6 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Wahn, Volker |e Sonstige |0 (DE-588)109550781 |4 oth | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=017121735&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-017121735 | ||
Datensatz im Suchindex
| _version_ | 1804138623895863296 |
|---|---|
| adam_text | Contents 13
Contents
^| The Biology of Antibody Synthesis 19
1.1. Antibodies - the Molecule 20
1.2. Antibodies - Mechanism of Action 22
1.2.1. IgM 22
1.2.2. IgD 22
1.2.3. IgG 23
1.2.4. IgA 23
1.2.5. IgE 23
1.3. The B Cell Repertoire 24
1.4. Peripheral B Cell Activation and Differentiation 24
1.5. Isotype Switching 26
1.6. Conclusion 28
1.7. References 28
H Pathogen Safety of Immunoglobulin Preparations 29
2.1. Plasma Source 31
2.1.1. Whole Blood or Plasma Donations 31
2.1.2. Selection of Donors and Mass Screening of Donations 31
2.2. Evaluating and Validating the Virus Safety of Intravenous Immunoglobulin G Preparations. 34
2.3. Virus Reduction During Fractionation of Immunoglobulin Preparations 36
2.3.1. Partitioning 37
2.3.2. Inactivation 38
2.3.3. The Introduction of Large-Scale Virus Filtration 39
2.3.4. Additional Virus Reduction and Inactivation Methods 40
2.4. Prion Safety of Immunoglobulin Preparations 40
2.4.1. Measures to Reduce the Theoretical Risk of vOD Transmission by Immunoglobulin Preparations 41
2.5. Cleaning and Traceability 42
2.5.1. Cleaning of Equipment in Contact with Product Prevents Carryover of Potentially Present
Pathogens from Batch to Batch 42
2.5.2. Traceability 43
2.6. Pharmacovigilance, Post-Marketing Studies and Surveillance Programs -
The Final Proof of Pathogen Safety of a Blood or Plasma Product 43
2.6.1. Virus Safety 43
2.6.2. The Risk of Transmission of Classical/Sporadic CID 43
2.6.3. The Risk of Transmission of Variant CID 44
2.7. Emerging Pathogens 44
^| Passive Immunoprophylaxis with Immunoglobulins 51
3.1. Definition 51
3.2. General Principles 51
3.3. Specific Immunoglobulin Preparations 51
3.4. Instructions for Use, Side Effects, Contraindications, Interactions 51
3.5. Indications for Passive Immunoprophylaxis 53
3.5.1. Hepatitis A 53
3.5.1.1. Principles 53
3.5.12. Passive Immunoprophylaxis 53
14 Contents
3.5.2. Hepatitis B 54
3.5.2.1. Principles 54
3.5.2.2. Passive Immunoprophylaxis 54
3.5.3. Measles 55
3.5.3.1. Principles 55
3.5.3.2. Passive Immunoprophylaxis 55
3.5.4. Rubella 55
3.5.4.1. Principles 55
3.5.4.2. Passive Immunoprophylaxis 55
3.5.5. Varicella 56
3.5.5.1. Principles 56
3.5.5.2. Passive Immunoprophylaxis 56
3.5.6. Cytomegalovirus Infection 57
3.5.6.1. Principles 57
3.5.6.2. Passive Immunoprophylaxis 57
3.6. Monoclonal Antibodies 57
3.6.1. Respiratory Syncytial Virus - Principles 57
3.6.2. Passive Immunoprophylaxis 57
3.7. Bacterial Toxins 58
3.7.1. Botulism 58
3.7.2. Immunoprophylaxis 58
3.7.3. Rabies 58
3.7.4. Diphtheria Toxin 58
3.7.5. Tetanus 59
3.8. References 59
m Sepsis in Neonates: Prevention and Adjuvant Therapy with Intravenous
Immunoglobulin 61
4.1. Immunoglobulin as Prophylaxis in Neonatal Infections 62
4.2. Immunoglobulin as Adjuvant Therapy for Neonatal Infections 65
4.3. Unsolved Problems 66
4.4. Recent Developments 67
4.5. Summary 68
4.6. References 69
m Application of Immunoglobulins in Other Infections 72
5.1. Exacerbation in Cystic Fibrosis 72
5.2. Infection with Respiratory Syncytial Virus 73
5.3. Infection with Rotaviruses 74
5.4. Bacterial Meningitis 74
5.5. Bacterial Sepsis 75
5.6. Streptococcal Toxic Shock-Like Syndrome 75
5.7. Hemolytic Uremic Syndrome 75
5.8. Recurrent Clostridium Difficile Colitis 76
5.9. Infant Botulism 76
5.10. References 77
i
Contents 15
m Use of Immunoglobulins in Congenital and Acquired Immunodeficiencies 79
6.1. Definitions 79
6.1.1. Primary Immunodeficiencies with B Cell Defects 79
6.1.2. Secondary Immunodeficiencies with B-Cell Defects 81
6.2. Frequency of Immunodeficiencies 81
6.3. Etiology/Pathogenesis 82
6.4. Clinical Findings in Antibody Deficiency Syndrome 82
6.5. Replacement Therapy with Immunoglobulins 83
6.5.1. Immunoglobulin Therapy in Primary Immunodeficiencies 83
6.5.1.1. Indications 83
6.5.1.2. Adverse Effects 84
6.5.1.3. Monitoring of Immunoglobulin Therapy 84
6.5.1.4. Infections Despite Immunoglobulin Replacement 85
6.5.1.4.1. Acute Respiratory Infections 85
6.5.1.4.2. Chronic Respiratory Infections 85
6.5.2. Immunoglobulin Therapy for Secondary Immunodeficiencies 85
6.5.2.1. Human Immunodeficiency Virus (HIV) 85
6.6. Summary and Conclusions 86
6.7. References 86
U IVIG Treatment of Secondary Immune Deficiencies in Adults 88
7.1. Immunity and Infection in Chronic Lymphocytic Leukemia and Multiple Myeloma 88
7.2. Therapy with IVIG in Chronic Lymphocytic Lymphoma and Multiple Myeloma 89
7.3. Hematopoetic Stem Cell Transplantation 91
7.4. References 91
U Immunomodulation with Immunoglobulins: Mechanisms 93
8.1. Release of Platelets from the Reticuloendothelial System (ITP) 93
8.2. Effects on Platelet-Associated IgG (ITP) 94
8.3. Accelerated Elimination of Circulating and Tissue-Bound Immune Complexes 94
8.4. Interaction with Fc Receptors (FcR) 94
8.5. Inhibition of Cell Adhesion by Natural RGD Antibodies 96
8.6. Effects on the Complement System 96
8.7. Disturbance of (Auto-)Antigen Presentation and Recognition 97
8.8. Interference with the Idiotype-Anti-ldiotype Network (anti-id-Ab) 98
8.9. Effects on Cytokines 99
8.9.1. Neutralization of Inflammatory Cytokines 99
8.9.2. Induction of Regulatory Cytokines and Receptor Antagonists 99
8.9.3. Inhibition of Cellular Responses to Interferon-y by Suppression of Expression of the IFNGR2
Receptor 100
8.10. Neutralization of Superantigens 100
8.11. Effects on Apoptosis 100
8.12. Summary 101
8.13. References 101
16 Contents
HI Use of immunoglobulins in Hematological Cytopenias 105
9.1. Thrombocytopenia 105
9.1.1. Acute Immune Thrombocytopenia 105
9.1.2. Neonatal Alloimmune Thrombocytopenia (AIT) 107
9.1.3. Maternal Autoimmune Thrombocytopenia During Pregnancy 108
9.1.4. Posttransfusion Purpura 108
9.1.5. Platelet Transfusions in Marked Alloimmunization 109
9.1.6. Gold-induced Thrombocytopenia 109
9.1.7. Heparin-induced Thrombocytopenia 109
9.1.8. Thrombocytopenia in the Hemolytic-Uremic Syndrome 109
9.1.9. Thrombotic Thrombocytopenic Purpura (Moschcowitz Syndrome) 109
9.1.10. HIV-Associated Thrombocytopenia 109
9.1.11. Chronic ITP 110
9.1.12. SLE-Associated Thrombocytopenia 112
9.1.13. Thrombocytopenia in Primary Antibody Deficiency Syndrome 112
9.2. Immune Hemolytic Anemia 112
9.2.1. Rhesus-Induced Alloimmune Hemolysis 112
9.2.2. ABO Isoimmune Hemolysis 113
9.2.3. Autoimmune Hemolytic Anemia and Evans Syndrome 113
9.3. Bone marrow aplasia 114
9.3.1. Erythroid Aplasia, Autoimmune Erythroblastopenia, Pure Red Cell Aplasia (PRCA) 114
9.3.2. Aplastic Anemia 114
9.4. Infection-Associated Hemophagocytosis Syndrome 114
9.5. Immune Neutropenia: Allo- and Autoimmune Neutropenia 115
9.6. References 116
If Further Applications of Immunoglobulin Therapy in
Pediatric Hematology/Oncology 122
10.1. Polyvalent Immunoglobulin Therapy in Pediatric Oncology Patients Undergoing
Chemotherapy 122
10.2. Application of Polyvalent Immunoglobulins in Allogeneic Hematopoietic Stem Cell
Transplantation 123
10.3. Application of Polyvalent Immunoglobulins in Hemophilia A/B with Inhibitor 124
10.4. References 125
m Use of Immunoglobulins in Rheumatologic Disorders and
Systemic Autoimmunopathies 127
11.1. Juvenile Idiopathic Arthritis: Systemic-Onset JIA and Polyarticular JIA 128
11.2. Rheumatoid Arthritis 130
11.3. Felty-Syndrome and Macrophage-Activation Syndrome 131
11.4. Systemic Lupus Erythematosus 131
11.5. Antiphospholipid Antibody Syndrome (APS) 133
11.6. Sclerodermatous Disorders and Mixed Connective Tissue Disorder 134
11.7. Crohn s Disease and Ulcerative Colitis 135
11.8. Uveitis 136
11.9. Summary and Concluding Remarks 136
11.10. References 136
Contents 17
| — - __ _
i ^| Use of Immunoglobulins for Kawasaki Disease and other Vasculitic
! Diseases 140
12.1. Kawasaki Disease (KD) 140
12.2. Polyarteritis Nodosa 144
12.3. ANCA-Positive Vasculitis, Wegener s Granulomatosis 144
12.4. Churg-Strauss Syndrome 145
12.5. IgA Nephropathy, Henoch-Schoenlein Purpura 145
12.6. Necrotizing Vasculitis 146
12.7. Livedo Vasculitis 146
12.8. Vasculitic Complications in Collagen Diseases 146
12.9. Summary 146
12.10. References 147
11 The Use of Immunoglobulins for Neurological Diseases in Children
and Adults 150
13.1. Multiple Sclerosis 150
13.2. Epilepsy 152
13.3. Non-Epileptic Encephalopathies in Children and Adolescents 156
13.4. Other CNS Diseases 157
13.5. Paraneoplastic Syndromes 158
13.6. Inflammatory Polyneuropathies 159
13.7. Myasthenia Gravis 165
13.8. Dermatomyositis, Polymyositis, Inclusion Body Myositis 167
13.9. References 170
^| Use of Intravenous Gammaglobulin (IVIG) in Kidney Transplantation 179
14.1. Desensitization for ABO Incompatible Transplantation 179
14.2. Immunomodulation with IVIG: Desensitization of Highly-HLA Sensitized Patients 180
14.2.1. Clinical Use of IVIG in Kidney Transplantation 180
14.2.2. The NIH IGO2 Study 180
14.2.3. Low-dose Intravenous Immunoglobulin and Plasmapheresis 181
14.2.4. IVIG + Rituximab for Desensitization 182
14.2.5. Complications and Cost of IVIG Therapy 182
14.2.6. IVIG and Acute Myocardial Infarction (AMI) 183
14.2.7. IVIG and Acute Renal Failure (ARF) 183
14.2.8. IVIG and Hemolytic Anemia 183
14.3. Adjunctive Therapy 184
14.3.1. Splenectomy and Anti-CD20 184
14.3.2. Kidney Paired Donation 184
14.4. Mechanism of Action of IVIG 185
14.5. Conclusion 186
14.6. References 186
18 Contents i
HJ Use of Immunoglobulins in Allergic Diseases 189
15.1. Bronchial Asthma 189
15.2. Atopic Dermatitis 190 I
15.3. Chronic Urticaria 190
15.4. Possible Mechanism of Action in Allergic Diseases 191 i
15.5. References 191 }
mi Further Indications for Intravenous Immunoglobulins 194
16.1. Graves-Basedow Disease (GBD) / Autoimmune Hyperthyroidism 194
16.2. Bullous Pemphigoid and Pemphigus Vulgaris 194
16.3. Toxic Epidermal Necrolysis (TEN, Lyell s Syndrome) and Stevens-Johnson s Syndrome 195
16.4. Toxic Shock Syndrome / Necrotising Fasciitis 196
16.5. Myocarditis and Congestive Chronic Heart Failure 197
16.6. Severe Acute Respiratory Syndrome (SARS) 197 !
16.7. Conclusion 197
16.8. References 198 i
m Intravenous Immunoglobulin in the Prevention of Recurrent Miscarriage 200
17.1. Studies of IVIG Treatment of RM 200
17.2. Patient Subsets and Treatment Protocols may Determine Outcome of IVIG Studies 201
17.2.1. Patient Subsets 201
17.2.2. Treatment Protocols 202
17.3. Negative Aspects of IVIG Use in RM 202
17.4. Conclusions 203
17.5. References 203
11 Index 205
|
| any_adam_object | 1 |
| author_GND | (DE-588)109550781 |
| building | Verbundindex |
| bvnumber | BV035317097 |
| ctrlnum | (OCoLC)461253218 (DE-599)DNB992051355 |
| dewey-full | 615.37 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.37 |
| dewey-search | 615.37 |
| dewey-sort | 3615.37 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| edition | 1. Aufl. |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01665nam a2200445 c 4500</leader><controlfield tag="001">BV035317097</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20090218 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">090217s2008 ad|| |||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">09,A08,0987</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">992051355</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783837410112</subfield><subfield code="c">(Bremen ...) Pp. : EUR 44.80</subfield><subfield code="9">978-3-8374-1011-2</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781848151284</subfield><subfield code="c">(London ...) Pp.</subfield><subfield code="9">978-1-84815-128-4</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)461253218</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB992051355</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield><subfield code="a">DE-20</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.37</subfield><subfield code="2">22/ger</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.37</subfield><subfield code="2">22//ger</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical use of immunoglobulins</subfield><subfield code="c">[Volker Wahn ; Jordan Orange. In collab. with Ama Alexis ...]</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1. Aufl.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Bremen [u.a.]</subfield><subfield code="b">UNI-MED-Verl.</subfield><subfield code="c">2008</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">207 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield><subfield code="c">25 cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">UNI-MED science</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Literaturangaben</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunglobulintherapie</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunization, Passive</subfield><subfield code="x">methods</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunoglobulins</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Immunglobulintherapie</subfield><subfield code="0">(DE-588)4161377-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Immunglobulintherapie</subfield><subfield code="0">(DE-588)4161377-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wahn, Volker</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)109550781</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=017121735&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-017121735</subfield></datafield></record></collection> |
| id | DE-604.BV035317097 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T21:31:08Z |
| institution | BVB |
| isbn | 9783837410112 9781848151284 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-017121735 |
| oclc_num | 461253218 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM DE-20 |
| owner_facet | DE-19 DE-BY-UBM DE-20 |
| physical | 207 S. Ill., graph. Darst. 25 cm |
| publishDate | 2008 |
| publishDateSearch | 2008 |
| publishDateSort | 2008 |
| publisher | UNI-MED-Verl. |
| record_format | marc |
| series2 | UNI-MED science |
| spelling | Clinical use of immunoglobulins [Volker Wahn ; Jordan Orange. In collab. with Ama Alexis ...] 1. Aufl. Bremen [u.a.] UNI-MED-Verl. 2008 207 S. Ill., graph. Darst. 25 cm txt rdacontent n rdamedia nc rdacarrier UNI-MED science Literaturangaben Immunglobulintherapie Immunization, Passive methods Immunoglobulins therapeutic use Immunglobulintherapie (DE-588)4161377-6 gnd rswk-swf Immunglobulintherapie (DE-588)4161377-6 s DE-604 Wahn, Volker Sonstige (DE-588)109550781 oth HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=017121735&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Clinical use of immunoglobulins Immunglobulintherapie Immunization, Passive methods Immunoglobulins therapeutic use Immunglobulintherapie (DE-588)4161377-6 gnd |
| subject_GND | (DE-588)4161377-6 |
| title | Clinical use of immunoglobulins |
| title_auth | Clinical use of immunoglobulins |
| title_exact_search | Clinical use of immunoglobulins |
| title_full | Clinical use of immunoglobulins [Volker Wahn ; Jordan Orange. In collab. with Ama Alexis ...] |
| title_fullStr | Clinical use of immunoglobulins [Volker Wahn ; Jordan Orange. In collab. with Ama Alexis ...] |
| title_full_unstemmed | Clinical use of immunoglobulins [Volker Wahn ; Jordan Orange. In collab. with Ama Alexis ...] |
| title_short | Clinical use of immunoglobulins |
| title_sort | clinical use of immunoglobulins |
| topic | Immunglobulintherapie Immunization, Passive methods Immunoglobulins therapeutic use Immunglobulintherapie (DE-588)4161377-6 gnd |
| topic_facet | Immunglobulintherapie Immunization, Passive methods Immunoglobulins therapeutic use |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=017121735&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT wahnvolker clinicaluseofimmunoglobulins |